The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: A pooled analysis of seven randomized, placebo-controlled studies

Human Psychopharmacology

Volumn 29, Issue 5, 2014, Pages 492-501

  Kornstein, Susan G ^a   Guico Pabia, Christine J ^b   Fayyad, Rana S ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Anxiety; Major depressive disorder; Treatment efficacy

Indexed keywords

DESVENLAFAXINE; DULOXETINE; PLACEBO; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SOMATIZATION; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ANXIETY; DEPRESSIVE DISORDER, MAJOR; META ANALYSIS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84922743342     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2427     Document Type: Article

References (34)

1. Akkaya C, Sivrioglu EY, Akgoz S, Eker SS, Kirli S. 2006. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. Hum Psychopharmacol 21: 337-345.
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th edn. American Psychiatric Publishing: Washington, DC.
3. American Psychiatric Association 2000. Diagnostic and Statistical Manual of Mental Disorders, Text Revision: DSM-IV-TR, 4 edn. American Psychiatric Publishing: Washington, DC.
4. Boyer P, Montgomery S, Lepola U, et al. 2008. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 23: 243-253.
5. Clayton A, Kornstein SG, Dunlop BW, et al. 2013. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of peri- and postmenopausal women with major depressive disorder. J Clin Psychiatry 74: 1010-1017.
6. Cleary P, Guy W. 1977. Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res 1: 115-120.
7. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. 2011. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 31: 569-576.
8. Farabaugh AH, Bitran S, Witte J, et al . 2010. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol 25: 214-217.
9. Fava M, Rankin MA, Wright EC, et al. 2000a. Anxiety disorders in major depression. Compr Psychiatry 41: 97-102.
10. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. 2000b. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59: 119-126.
11. Fava M, Alpert JE, Carmin CN, et al. 2004. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR∗D. Psychol Med 34: 1299-1308.
12. Fava M, Rush AJ, Alpert JE, et al. 2006. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 51: 823-835.
13. Fava M, Rush AJ, Alpert JE, et al. 2008. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report. Am J Psychiatry 165: 342-351.
14. Guy W. 1976. Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology, US Department of Health, Education, and Welfare: Rockville, MD; 217-222.
15. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
16. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
17. Iwata N, Tourian KA, Hwang E, Mele L, Vialet C, for the Study 3359 Investigators. 2013. Efficacy and safety of desvenlafaxine 25 and 50 mg/d in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 19: 5-14.
18. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. 2008. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 24: 1877-1890.
19. Liebowitz MR, Tourian KA, Hwang E, Mele L, for the Study 3362 Investigators. 2013. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry 13: 94.
20. Lipman RS. 1982. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 18: 69-77.
21. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
22. Nelson JC. 2010. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety 27: 12-18.
23. Papakostas GI, Clain A, Ameral VE, et al. 2010. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol 25: 17-21.
24. Papakostas GI, Fan H, Tedeschini E. 2011. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol.
25. Pristiq [package insert]. 2013. Wyeth Pharmaceuticals, Inc, a Subsidiary of Pfizer Inc, Philadelphia, PA.
26. Rush AJ, Fava M, Wisniewski SR, et al. 2004. Sequenced treatment alternatives to relieve depression (STAR∗D): rationale and design. Control Clin Trials 25: 119-142.
27. Russell JM, Koran LM, Rush J, et al. 2001. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 13: 18-27.
28. Seo HJ, Jung YE, Kim TS, et al. 2011. Distinctive clinical characteristics and suicidal tendencies of patients with anxious depression. J Nerv Ment Dis 199: 42-48.
29. Sheehan, DV. 2000. Sheehan Disability Scale. In Handbook of Psychiatric Measures, Rush AJ, Pincus HA, First MB (eds). American Psychiatric Association: Washington, DC; 113-115.
30. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D. 2009. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 31:(Pt 1): 1405-1423.
31. Uher R, Dernovsek MZ, Mors O, et al. 2011. Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord 132: 112-120.
32. Wiethoff K, Bauer M, Baghai TC, et al. 2010. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. J Clin Psychiatry 71: 1047-1054.
33. World Health Organization. Wellbeing measures in primary health care/the DepCare project. World Health Organization. 1998. World Health Organization Regional Office for Europe. 3-20-2012. Ref Type: Electronic Citation
34. Zimmerman M, Chelminski I, McDermut W. 2002. Major depressive disorder and axis I diagnostic comorbidity. J Clin Psychiatry 63: 187-193.